Investing in a
healthier future.
A glimpse at
our Portfolio.
Precision medicine for the brain is here. Alto is pioneering an approach to psychiatric drug development which matches the patient with the most promising treatment based on AI-derived brain biomarkers.
Cambrian is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan – the period of life spent in good health.
Refoxy is developing therapeutic medicines intended to treat age-related diseases and improve healthy longevity by focusing on FOXO modulators.
Precision medicine for the brain is here. Alto is pioneering an approach to psychiatric drug development which matches the patient with the most promising treatment based on AI-derived brain biomarkers.
Cambrian is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan – the period of life spent in good health.
Refoxy is developing therapeutic medicines intended to treat age-related diseases and improve healthy longevity by focusing on FOXO modulators.
Backing breakthrough technologies in longevity and mental health.
We want people to be able to live long, healthy, and fulfilled lives. Therefore, we aim to back the most promising companies in longevity and mental health, which focus on redefining the sectors as we know them. We form our portoflio by investing in unique approaches led by pioneering teams. Our investment focus is investing in Series A – C rounds into companies that have strong traction, achieved proof of concept, and are positioned to be future leaders in their respective field.
Latest
insights.
‘Biotech is the ultimate impact investment’ — family offices can’t get enough of it
Interactive Strength Inc. d/b/a FORME Announces Pricing of $12 Million Initial Public Offering
Personalisierte Medizin: Health-Tech-Startup Aera Health sammelt 4 Millionen Euro ein
Alto Neuroscience Wins 2022 BioTech Breakthrough and BioSpace’s 2023 Best Places to Work Awards
Press Release: James Peyer Named 2022 “BioTech Company CEO of the Year” By BioTech Breakthrough
Alto Neuroscience Announces $35 Million Series B Financing
Second Rejuveron Company Transitions into Clinical Stage
Get involved
for further information.
Please contact us anytime should you have questions. We are looking forward to getting in touch with you.